Rhumbline Advisers Acquires 3,623 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Rhumbline Advisers increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 1.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 216,296 shares of the medical equipment provider's stock after acquiring an additional 3,623 shares during the period. Rhumbline Advisers owned about 0.31% of Lantheus worth $21,110,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. abrdn plc boosted its holdings in Lantheus by 18.7% during the 4th quarter. abrdn plc now owns 7,159 shares of the medical equipment provider's stock worth $640,000 after acquiring an additional 1,127 shares during the last quarter. Retirement Systems of Alabama lifted its position in shares of Lantheus by 128.9% during the fourth quarter. Retirement Systems of Alabama now owns 193,101 shares of the medical equipment provider's stock valued at $17,275,000 after purchasing an additional 108,759 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock worth $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Bleakley Financial Group LLC grew its position in Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after purchasing an additional 129 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Lantheus by 32.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 8,764 shares of the medical equipment provider's stock valued at $784,000 after buying an additional 2,127 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, Truist Financial reduced their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $132.67.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director now directly owns 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,068 shares of company stock worth $3,008,051 in the last quarter. Insiders own 1.50% of the company's stock.

Lantheus Price Performance

Shares of Lantheus stock traded down $2.80 on Tuesday, reaching $80.42. 1,190,596 shares of the company traded hands, compared to its average volume of 1,005,876. The company has a 50 day moving average of $89.64 and a 200 day moving average of $91.61. Lantheus Holdings, Inc. has a 52 week low of $73.11 and a 52 week high of $126.89. The firm has a market capitalization of $5.56 billion, a PE ratio of 13.38 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the previous year, the business earned $1.69 EPS. The company's revenue for the quarter was up .8% on a year-over-year basis. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.